Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience Journal Article
| Authors: | Kothari, P.; Marass, F.; Yang, J. L.; Stewart, C. M.; Stephens, D.; Patel, J.; Hasan, M.; Jing, X.; Meng, F.; Enriquez, J.; Huberman, K.; Viale, A.; Francis, J. H.; Berger, M. F.; Shukla, N.; Abramson, D. H.; Dunkel, I. J.; Tsui, D. W. Y. |
| Article Title: | Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience |
| Abstract: | Purpose: The enucleation rate for retinoblastoma has dropped from over 95% to under 10% in the past 10 years as a result of improvements in therapy. This reduces access to tumor tissue for molecular profiling, especially in unilateral retinoblastoma, and hinders the confirmation of somatic RB1 mutations necessary for genetic counseling. Plasma cell-free DNA (cfDNA) has provided a platform for noninvasive molecular profiling in cancer, but its applicability in low tumor burden retinoblastoma has not been shown. We analyzed cfDNA collected from 10 patients with available tumor tissue to determine whether sufficient tumorderived cfDNA is shed in plasma from retinoblastoma tumors to enable noninvasive RB1 mutation detection. Methods: Tumor tissue was collected from eye enucleations in 10 patients diagnosed with advanced intra-ocular unilateral retinoblastoma, three of which went on to develop metastatic disease. Tumor RB1 mutation status was determined using an FDA-cleared tumor sequencing assay, MSK-IMPACT. Plasma samples were collected before eye enucleation and analyzed with a customized panel targeting all exons of RB1. Results: Tumor-guided genotyping detected 10 of the 13 expected somatic RB1 mutations in plasma cfDNA in 8 of 10 patients (average variant allele frequency 3.78%). Without referring to RB1 status in the tumor, de novo mutation calling identified 7 of the 13 expected RB1 mutations (in 6 of 10 patients) with high confidence. Conclusion: Plasma cfDNA can detect somatic RB1 mutations in patients with unilateral retinoblastoma. Since intraocular biopsies are avoided in these patients because of concern about spreading tumor, cfDNA can potentially offer a noninvasive platform to guide clinical decisions about treatment, follow-up schemes, and risk of metastasis. © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. |
| Keywords: | clinical article; human tissue; gene mutation; human cell; exon; gene; metastasis; cohort analysis; genotype; gene frequency; retinoblastoma; infant; dna fingerprinting; eye enucleation; cancer tissue; cell free system; proof of concept; rb1 gene; human; priority journal; article; liquid biopsy; plasma cell-free dna; molecular profiling in retinoblastoma; rb1 mutation |
| Journal Title: | Cancer Medicine |
| Volume: | 9 |
| Issue: | 17 |
| ISSN: | 2045-7634 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2020-09-01 |
| Start Page: | 6093 |
| End Page: | 6101 |
| Language: | English |
| DOI: | 10.1002/cam4.3144 |
| PUBMED: | 32633890 |
| PROVIDER: | scopus |
| PMCID: | PMC7476838 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work